Arrowhead Pharmaceuticals has completed patient enrolment in the Phase l AROAAT1001 trial of ARO-AAT for Treatment of Alpha-1 Liver Disease.

The single and multiple-ascending dose clinical trial is designed to investigate the safety, tolerability, pharmacokinetics, and effect of ARO-AAT on serum alpha-1 antitrypsin levels in healthy adult subjects.

It comprises seven cohorts where 16 subjects receive placebo and 28 subjects receive single or multiple doses of ARO-AAT at doses of 35mg, 100mg, 200mg, or 300mg.

Arrowhead also planned to include additional cohorts at a dose of 400mg, but terminated the plan after the maximal activity appeared to take place at lower doses than expected.

The primary endpoint of the AROAAT1001 trial is the number of participants with adverse events (AEs) possibly or probably related to treatment.

“We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated.”

The secondary endpoints include pharmacokinetics (PK), percentage change in serum alpha-1 antitrypsin (aat) levels and duration of response of serum AAT levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial is expected to be completed by February next year.

Arrowhead Pharmaceuticals president and CEO Chris Anzalone said: “The ARO-AAT Phase l study provides the first readout on pharmacologic activity for a therapeutic leveraging our proprietary Targeted RNAi Molecule, or TRiM, platform.

“We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated.”

ARO-AAT is an investigational subcutaneously administered RNA interference (RNAi) therapeutic that could be used as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.